This year, the Top Employers Institute has certified over 2,400 organizations from 125 countries and regions across five continents. In Romania's pharmaceutical industry, only four companies have received this recognition in 2025, with Novartis among them. The Top Employer certification highlights the company's commitment to creating an outstanding work environment and reflects excellence in implementing best practices in areas such as HR strategy, work environment, recruitment, continuous learning, diversity, equity, and inclusion, as well as employee well-being.

"We are honored by this recognition, which reflects our values and commitment to building an organization where every employee has the opportunity to reach their full potential. Together with over 550 employees, we are developing a strong organizational culture and creating an environment that not only enhances performance but also supports and encourages continuous learning. At the same time, as a company specializing in research and development, we are dedicated to transforming science into innovative treatments that provide real value for patients. Novartis is an innovative medicines company with a manufacturing unit in Romania, and we are proud of our significant contribution to improving the health of Romanian patients," said Marcelo Rainer, Country President and General Manager of Novartis Romania.

Novartis Romania operates through two distinct legal entities, one managing the import and distribution of innovative medicines, headquartered in Bucharest, and the other overseeing manufacturing operations at the Târgu Mureș plant. Locally, Novartis markets over 60 original medicines, which have contributed to gaining over 12,000 healthy life years (QALY) for Romanian patients. In 2023, the Târgu Mureș plant produced over 116 million treatments, distributed both locally and internationally.

Novartis' activity focuses on four key therapeutic areas: cardiovascular, renal, and metabolic diseases, immunology, neurological disorders, oncology. At the same time, the company is investing in five cutting-edge technology platforms: synthetic chemistry-based products, biotherapeutic (biologic) medicines, RNA-based therapies, radioligand therapies, gene and cell therapies.

The company remains a pioneer in pharmaceutical innovation in Romania, being the first to introduce revolutionary therapies, such as cell therapy for a type of blood cancer (2022) and gene therapy for spinal muscular atrophy (SMA). Additionally, in the near future, radioligand therapy will become available for patients with advanced prostate cancer. Through these advancements, Novartis is significantly contributing to raising Romania's healthcare standards, offering patients access to cutting-edge treatments for conditions such as cancer, cardiovascular diseases, rare diseases, and many others.